Industry responsibility in interactive computer modeling

Medical Care

Volumn 34, Issue 12 SUPPL., 1996, Pages

  Mauskopf, Josephine ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Computer modeling, pharmacoeconomics; Methodological standards, pharmacoeconomics; Transparency standards, pharmacoeconomics

Indexed keywords

ARTICLE; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DRUG THERAPY; HUMAN; PHARMACOECONOMICS; STANDARD;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; HUMANS;

EID: 0030331486     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Clemens K, Townsend R, Luscombe F, Mauskopf J, et al. Methodological and conduct principles for pharmacoeconomic research. Pharmacoeconomics 1995;8:169.
2. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: A report on principles. Ann Intern Med 1995;122:61.
3. Canadian Coordinating Office on Health Technology Assessment (CCOHTA). 1994 Guidelines for economic evaluation of pharmaceuticals, 1st ed. Ottawa: CCOHTA, 1994.
4. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including submissions involving economic analyses. Canberra: Department of Health, Housing, and Community Services, 1992.
5. Luce B, Simpson K. Methods of cost-effectiveness analysis: Areas of consensus and debate. Clin Therapeutics 1995;17:109.
6. Oster G, Huse DM, Delea TE, et al. The risks and benefits of an Rx-to-OTC switch: The case of over-the-counter H2-blockers. Med Care 1990;28:834.
7. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994;330:738.
8. O'Brien B, Drummond M, Labelle R, et al. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994;32:150.
9. Van Hout BA, Ae MJ, Gordon GS, et al. Costs, effects, and C/E ratios alongside a clinical trial. Health Economics 1994;3:309.
10. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473.
11. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications. Draft principles for the review of pharmacoeconomic promotion. 1992.
12. Smith T, Hillner B, Neighbors D, et al. An economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol 1995;13:2166.